<DOC>
	<DOCNO>NCT00101192</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Cetuximab may also help cisplatin work well make tumor cell sensitive drug . Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving cetuximab together cisplatin may better way block tumor growth . PURPOSE : This phase II trial study well give cetuximab together cisplatin work treat patient advance , persistent , recurrent cervical cancer .</brief_summary>
	<brief_title>Cetuximab Cisplatin Treating Patients With Advanced , Persistent , Recurrent Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine antitumor activity cetuximab cisplatin , term objective tumor response ( partial complete ) , patient advance , persistent , recurrent carcinoma cervix . - Determine nature degree toxicity regimen patient . Secondary - Determine progression-free survival overall survival patient treat regimen . - Correlate epidermal growth factor receptor expression progression-free survival , overall survival , response patient treat regimen . OUTLINE : This multicenter study . Patients receive cetuximab IV 1-2 hour day 1 , 8 , 15 cisplatin IV day 1 8 . Courses repeat every 21 day absence unacceptable toxicity disease progression . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 28-62 patient accrue study within 9-20 month .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous nonsquamous cell carcinoma cervix Advanced , persistent , recurrent disease Documented disease progression Not amenable curative therapy Measurable disease At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan At least 1 target lesion Tumors within previously irradiate field designate nontarget lesion unless progression document biopsy obtain ≥ 90 day completion radiotherapy confirm persistence PATIENT CHARACTERISTICS : Age 18 Performance status GOG 02 Life expectancy Not specify Hematopoietic Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Renal Creatinine ≤ 1.5 time ULN Cardiovascular No significant history cardiac disease within past 6 month , include follow : Unstable angina Uncontrolled hypertension Uncontrolled congestive heart failure Uncontrolled arrhythmia Neurologic No uncontrolled seizure disorder No active neurological disease No neuropathy ( sensory motor ) &gt; grade 1 Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection require antibiotic No invasive malignancy within past 5 year except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy No prior antiepidermal growth factor receptor ( EGFR ) antibody therapy No prior chimerized murine monoclonal antibody therapy Chemotherapy Not specify Endocrine therapy At least 1 week since prior anticancer hormonal therapy Concurrent hormone replacement therapy allow Radiotherapy See Disease Characteristics At least 4 week since prior radiotherapy Surgery More 30 day since prior major surgery , except diagnostic biopsy Other Recovered prior therapy No prior cytotoxic therapy cervical cancer No prior tyrosine kinase inhibitor therapy target EGFR pathway No prior cancer treatment would contraindicate study therapy No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
	<keyword>cervical small cell carcinoma</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
</DOC>